Use of andrographolide in treatment of calcific aortic valve disease

A technology of andrographolide and calcification, which is applied to cardiovascular system diseases, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problem of high perioperative mortality, increased financial burden on patients' families, and poor long-term effects Good and other questions

Pending Publication Date: 2020-05-05
XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, surgery will inevitably bring higher risks to patients, such as high perioperative mortality rate, poor long-term effect, and at the same time increase the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of andrographolide in treatment of calcific aortic valve disease
  • Use of andrographolide in treatment of calcific aortic valve disease
  • Use of andrographolide in treatment of calcific aortic valve disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1. Construction of a human valve mesenchymal cell calcification model induced by a commercial osteogenic induction medium

[0024] Take valvular interstitial cells with a culture density close to 80%, starve them overnight with 2% FBS+DMEM high-sugar culture solution, and then complete the starvation with a newly prepared osteogenic induction medium (Cyagen, product number: HUXMA-90021) The calcification of the valvular interstitial cells was induced, and alizarin red staining was performed after 21 days of induction to investigate the effects of different treatments on the calcification of the valvular interstitial cells.

Embodiment 2

[0025] Example 2, andrographolide inhibits calcification of human valve interstitial cells

[0026] The human valve interstitial cell calcification model constructed as in Example 1 above was used, and the human valve interstitial cells were divided into 3 groups, namely control group (untreated), OM group (osteogenic medium induction) and OM+AGP group (andrographolide was added after osteogenic medium induction). Human valve interstitial cells were treated with different concentrations of andrographolide (andrographolide was purchased from Selleck, catalog number: S2261), and IC50 test, CCK8 determination and alizarin red staining analysis were performed.

[0027] IC50 results as figure 1 Shown in B. cck8 cell viability detection, the concentration of 10μM andrographolide did not show obvious cytotoxicity, and did not affect the cell morphology ( figure 1 C and 1D). After 21 days of treatment of human valve mesenchymal cells with osteogenic medium, alizarin red staining w...

Embodiment 3

[0028] Example 3, andrographolide inhibits human valve interstitial cell calcification gene protein expression

[0029] The human valve interstitial cell calcification model constructed as in Example 1 above was used, and the human valve interstitial cells were divided into 3 groups, namely control group (untreated), OM group (osteogenic medium induction) and OM+AGP group (andrographolide was added after osteogenic medium induction). Human valve mesenchymal cells were treated with 10 μM final concentration of andrographolide (final concentration in culture medium), and osteogenesis-specific genes RUNX2 and ALPL were detected at 24h and 48h.

[0030] Quantitative qRT-PCR results showed that the expression of ALP and RUNX2 (osteogenic differentiation marker gene) was significantly upregulated by osteogenic medium compared with the control group (*p figure 2 a and 2b), showing a statistically significant difference (#p figure 2 c and 2d). Protein expression was verified in anoth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the field of prevention and/or treatment of calcific aortic valve disease. Researches show that andrographolide can effectively down-regulate expressions of osteogenicdifferentiation marker genes RUNX2 and ALP in valvular interstitial cells, inhibit valvular interstitial cell calcification, and thus inhibit or delay valve calcification, thereby providing a use ofthe andrographolide in preparation of medicines for preventing and/or treating the individual calcific aortic valve disease. A new option for using a non-surgical method to treat the calcific aortic valve disease is provided.

Description

technical field [0001] The invention relates to the field of prevention and / or treatment of aortic valve calcification, in particular to the use of andrographolide in the prevention and / or treatment of aortic valve calcification. Background technique [0002] Andrographolide (AGP) is a natural diterpenoid extracted from the traditional Chinese herbal medicine Andrographis paniculata, which has been proven to have anti-inflammatory, anti-atherosclerotic, and anti-tumor activities. Studies have demonstrated that AGP can produce moderate anti-inflammatory activity in vivo, in vitro and in chronic inflammation models without adverse effects on the gastric mucosa. Another study demonstrated that AGP can inhibit iNOS (inducible nitric oxide synthase) protein expression in macrophages. Inhibition of NO production is considered a key therapeutic role of AGP because high levels of NO can lead to tissue damage. At present, andrographolide has been proven to have a role in viral myoc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/365A61P9/00
CPCA61K31/365A61P9/00
Inventor 许康董念国黄玉明刘名周廷文
Owner XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap